Bioactive Milk Peptides and Blood Pressure

Stage 1 Hypertension Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01031485
• Other study ID #: Valio-70
• Status: Completed
• Phase: Phase 3
• First received: December 11, 2009
• Last updated: December 19, 2014
• Start date: January 2010
• Est. completion date: August 2010

Study information

• Verified date: December 2009
• Source: Valio Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of bioactive milk peptides on blood pressure in mildly hypertensive subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: August 2010
• Est. primary completion date: June 2010
• Gender: Both
• Age group: 30 Years to 60 Years

Eligibility

Inclusion Criteria:

• age 30-60 years

• systolic blood pressure 140-160 mmHg and diastolic blood pressure 90-99 mmHg in office measurement

• apparently healthy

Exclusion Criteria:

• antihypertensive and lipid-lowering drugs

• unstable coronary artery disease, diabetes, malignant diseases, secondary hypertension

• BMI > 32 kg/m2

• milk allergy

• smoking

• alcohol abuse

• pregnancy, lactation

• simultaneous participation in other clinical trial

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind

Related Conditions & MeSH terms

• Stage 1 Hypertension

Intervention

Dietary Supplement:
• Milk peptides and plant sterols

Other:
• Placebo

Locations

Country	Name	City	State
Finland	Valio Ltd	Helsinki	Uusimaa

Sponsors (2)

Lead Sponsor	Collaborator
Valio Ltd	Helsinki University

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood pressure